These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27791402)

  • 1. Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.
    Garcia CA; Wu S
    Cancer Invest; 2016 Nov; 34(10):521-530. PubMed ID: 27791402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
    Shameem R; Lacouture M; Wu S
    Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
    Shameem R; Lacouture M; Wu S
    Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
    Shameem R; Hamid MS; Wu S
    Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
    Qi WX; Huang YJ; Yao Y; Shen Z; Min DL
    PLoS One; 2013; 8(6):e65166. PubMed ID: 23785409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
    Peng L; Zhou Y; Ye X; Zhao Q
    Tumour Biol; 2015 Feb; 36(2):643-54. PubMed ID: 25281033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):477-86. PubMed ID: 25665062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.
    Choueiri TK; Je Y; Sonpavde G; Richards CJ; Galsky MD; Nguyen PL; Schutz F; Heng DY; Kaymakcalan MD
    Ann Oncol; 2013 Aug; 24(8):2092-7. PubMed ID: 23658373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic complications with the use of mTOR inhibitors for cancer therapy.
    Sivendran S; Agarwal N; Gartrell B; Ying J; Boucher KM; Choueiri TK; Sonpavde G; Oh WK; Galsky MD
    Cancer Treat Rev; 2014 Feb; 40(1):190-6. PubMed ID: 23684373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.
    Iacovelli R; Palazzo A; Mezi S; Morano F; Naso G; Cortesi E
    Acta Oncol; 2012 Sep; 51(7):873-9. PubMed ID: 22909392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis.
    Xu KY; Shameem R; Wu S
    Acta Oncol; 2016; 55(9-10):1196-1203. PubMed ID: 27142123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis.
    Ramirez-Fort MK; Case EC; Rosen AC; Cerci FB; Wu S; Lacouture ME
    Am J Clin Oncol; 2014 Jun; 37(3):266-71. PubMed ID: 23241507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
    Nozawa M; Ohzeki T; Tamada S; Hongo F; Anai S; Fujimoto K; Miki T; Nakatani T; Fukasawa S; Uemura H
    Int J Clin Oncol; 2015 Aug; 20(4):790-5. PubMed ID: 25342378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors.
    Kaymakcalan MD; Je Y; Sonpavde G; Galsky M; Nguyen PL; Heng DY; Richards CJ; Choueiri TK
    Br J Cancer; 2013 Jun; 108(12):2478-84. PubMed ID: 23736025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
    Jebali M; Elaidi R; Brizard M; Fouque J; Takouchop C; Sabatier B; Oudard S; Medioni J
    BMC Cancer; 2017 Jan; 17(1):27. PubMed ID: 28061764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
    Kordes S; Klümpen HJ; Weterman MJ; Schellens JH; Richel DJ; Wilmink JW
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1135-41. PubMed ID: 25822310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Metabolic Complications in Patients with Solid Tumors Treated with mTOR inhibitors: Meta-analysis.
    Lew S; Chamberlain RS
    Anticancer Res; 2016 Apr; 36(4):1711-8. PubMed ID: 27069150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR Inhibition and Cardiovascular Diseases: Dyslipidemia and Atherosclerosis.
    Kurdi A; Martinet W; De Meyer GRY
    Transplantation; 2018 Feb; 102(2S Suppl 1):S44-S46. PubMed ID: 28230638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
    Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
    Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.